Keywords: update, gsk, signs, upto, 670m, deal, retigabine

UPDATE: GSK signs upto $670M deal for retigabine

Article | 08 September 2008

UK drug major GlaxoSmithKline and California, USA-based Valeant Pharmaceuticals have entered into an exclusive worldwide collaboration for the investigational drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

GSK

Valeant Pharmaceuticals

Go to company listing